We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
- Authors
Rossari, Federico; Minutolo, Filippo; Orciuolo, Enrico
- Abstract
Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t(9, 22)-derived Philadelphia chromosome. Although the specific targeting of that oncoprotein, several Bcr-Abl-dependent and Bcr-Abl-independent mechanisms of resistance to imatinib arose after becoming first-line therapy in chronic myelogenous leukemia (CML) treatment. Consequently, new specific drugs, namely dasatinib, nilotinib, bosutinib, and ponatinib, were rationally designed and approved for clinic to override resistances. Imatinib fine mechanisms of action had been elucidated to rationally develop those second- and third-generation inhibitors. Crystallographic and structure-activity relationship analysis, jointly to clinical data, were pivotal to shed light on this topic. More recently, preclinical evidence on bafetinib, rebastinib, tozasertib, danusertib, HG-7-85-01, GNF-2, and 1,3,4-thiadiazole derivatives lay promising foundations for better inhibitors to be approved for clinic in the near future. Notably, structural mechanisms of action and drug design exemplified by Bcr-Abl inhibitors have broad relevance to both break through resistances in CML treatment and develop inhibitors against other kinases as targeted chemotherapeutics.
- Subjects
PROTEIN-tyrosine kinases; IMATINIB; CHRONIC myeloid leukemia; TREATMENT of chronic myeloid leukemia; STRUCTURE-activity relationship in pharmacology; PATIENTS
- Publication
Journal of Hematology & Oncology, 2018, Vol 11, Issue 1, pN.PAG
- ISSN
1756-8722
- Publication type
Article
- DOI
10.1186/s13045-018-0624-2